Activation-induced cell death limits effector function of CD4 tumor-specific T cells

Journal of Immunology

Volumn 172, Issue 11, 2004, Pages 6598-6606

  Saff, Rebecca R ^a   Spanjaard, Elena S ^a   Hohlbaum, Andreas M ^b   Marshak Rothstein, Ann ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pieris Pharmaceuticals GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL ACTIVITY; CELL DEATH; CELL FUNCTION; CELL SPECIFICITY; CONTROLLED STUDY; DO11 TH1 CELL; EFFECTOR CELL; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR GROWTH; TUMOR REGRESSION; UPREGULATION; WILD TYPE;

EID: 2442709068     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.11.6598     Document Type: Article

References (61)

1. Ju, S. T., D. J. Panka, H. Cui, R. Ettinger, M. el-Khatib, D. H. Sherr, B. Z. Stanger, and A. Marshak-Rothstein. 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373:444.
2. Wofsy, D., E. D. Murphy, J. B. Roths, M. J. Dauphinee, S. B. Kipper, and N. Talal. 1981. Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene. J. Exp. Med. 154:1671.
3. + T lymphocytes from MRL/lpr mice are resistant to receptor-mediated tolerance and apoptosis. J. Immunol. 151:7233.
4. Allison, J., H. M. Georgiou, A. Strasser, and D. L. Vaux. 1997. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94:3943.
5. Seino, K., N. Kayagaki, K. Fukao, K. Okumura, and H. Yagita. 1997. Rejection of Fas ligand-expressing grafts. Transplant. Proc. 29:1092.
6. Shimizu, M., A. Fontana, Y. Takeda, H. Yagita, T. Yoshimoto, and A. Matsuzawa. 1999. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells. J. Immunol. 162:7350.
7. Hohlbaum, A. M., S. Moe, and A. Marshak-Rothstein. 2000. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J. Exp. Med. 191:1209.
8. Hohlbaum, A. M., M. S. Gregory, S. T. Ju, and A. Marshak-Rothstein. 2001. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J. Immunol. 167:6217.
9. Van Parijs, L., and A. K. Abbas. 1998. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280:243.
10. - T cells: tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161:1122.
11. + helper T cells are required for resistance to a highly metastatic murine tumor. Eur. J. Immunol. 17:1863.
12. Romerdahl, C. A., and M. L. Kripke. 1988. Role of helper T-lymphocytes in rejection of UV-induced murine skin cancers. Cancer Res. 48:2325.
13. + T cells in the antitumor immune response. J. Exp. Med. 188:2357.
14. + T cell help. J. Exp. Med. 186:65.
15. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480.
16. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478.
17. + T-helper and a T-killer cell. Nature 393:474.
18. Kalams, S. A., and B. D. Walker. 1998. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188:2199.
19. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:8056.
20. Hernberg, M. 1999. Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy. Med. Oncol. 16:145.
21. Zaks, T. Z., D. B. Chappell, S. A. Rosenberg, and N. P. Restifo. 1999. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J. Immunol. 162:3273.
22. Cohn, L., J. S. Tepper, and K. Bottomly. 1998. IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells. J. Immunol. 161:3813.
23. + T cells. J. Immunol. 150:1691.
24. Mauri, D., T. Wyss-Coray, C. Brander, and W. J. Pichler. 1994. Improved sensitization of antigen-presenting cells with transferrin-bound peptides: advantages in competition for antigen presentation. Cell. Immunol. 158:59.
25. Fernandes, D. M., L. Vidard, and K. L. Rock. 2000. Characterization of MHC class II-presented peptides generated from an antigen targeted to different endocytic compartments. Eur. J. Immunol. 30:2333.
26. Zaliauskiene, L., S. Kang, K. Sparks, K. R. Zinn, L. M. Schwiebert, C. T. Weaver, and J. F. Collawn. 2002. Enhancement of MHC class II-restricted responses by receptor-mediated uptake of peptide antigens. J. Immunol. 169:2337.
27. Sallusto, F., E. Kremmer, B. Palermo, A. Hoy, P. Ponath, S. Qin, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur. J. Immunol. 29:2037.
28. Burastero, S. E., G. A. Rossi, and E. Crimi. 1998. Selective differences in the expression of the homing receptors of helper lymphocyte subsets. Clin. Immunol. Immunopathol. 89:110.
29. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 10:588.
30. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA 96:8633.
31. Rosenberg, S. A. 2001. Progress in human tumor immunology and immunotherapy. Nature 411:380.
32. Ossendorp, F., E. Mengede, M. Camps, R. Filius, and C. J. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187:693.
33. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747.
34. Yang, Y., and J. M. Wilson. 1996. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 273:1862.
35. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
36. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281.
37. Sun, J. C., and M. J. Bevan. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300:339.
38. Shedlock, D. J., and H. Shen. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337.
39. + T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit. Rev. Immunol. 20:17.
40. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN γ receptor expression by nonhematopoietic cells. Immunity 12:677.
41. + T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J. Immunol. 146:3235.
42. Ten Hagen, T. L., A. M. Eggermont, and F. J. Lejeune. 2001. TNF is here to stay: revisited. Trends Immunol. 22:127.
43. Lejeune, F., D. Lienard, A. Eggermont, H. Schraffordt Koops, F. Rosenkaimer, J. Gerain, J. Klaase, B. Kroon, J. Vanderveken, and P. Schmitz. 1994. Rationale for using TNF α and chemotherapy in regional therapy of melanoma. J. Cell. Biochem. 56:52.
44. Blankenstein, T., Z. H. Qin, K. Uberla, W. Muller, H. Rosen, H. D. Volk, and T. Diamantstein. 1991. Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer. J. Exp. Med. 173:1047.
45. Qin, Z., S. Kruger-Krasagakes, U. Kunzendorf, H. Hock, T. Diamantstein, and T. Blankenstein. 1993. Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis. J. Exp. Med. 178:355.
46. Snijders, A., P. Kalinski, C. M. Hilkens, and M. L. Kapsenberg. 1998. High-level IL-12 production by human dendritic cells requires two signals. Int. Immunol. 10:1593.
47. Loza, M. J., and B. Perussia. 2001. Final steps of natural killer cell maturation: a model for type 1-type 2 differentiation? Nat. Immunol. 2:917.
48. Austrup, F., D. Vestweber, E. Borges, M. Lohning, R. Brauer, U. Herz, H. Renz, R. Hallmann, A. Scheffold, A. Radbruch, and A. Hamann. 1997. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues. Nature 385:81.
49. + T cells migrate into inflamed skin only if they express ligands for E- and P-selectin. J. Immunol. 161:963.
50. + T cells. J. Exp. Med. 189:1765.
51. Lim, Y. C., L. Henault, A. J. Wagers, G. S. Kansas, F. W. Luscinskas, and A. H. Lichtman. 1999. Expression of functional selectin ligands on Th cells is differentially regulated by IL-12 and IL-4. J. Immunol. 162:3193.
52. Shimizu, Y., G. A. Van Seventer, K. J. Horgan, and S. Shaw. 1990. Regulated expression and binding of three VLA (β1) integrin receptors on T cells. Nature 345:250.
53. Jager, D., E. Jager, and A. Knuth. 2001. Immune responses to tumor antigens: implications for antigen specific immunotherapy of cancer. J. Clin. Pathol. 54:669.
54. Nguyen, B., L. W. Elmore, and S. E. Holt. 2003. Telomerase as a target for cancer immunotherapy. Cancer Biol. Ther. 2:131.
55. + T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res. 62:5041.
56. Su, Z., J. Dannull, A. Heiser, D. Yancey, S. Pruitt, J. Madden, D. Coleman, D. Niedzwiecki, E. Gilboa, and J. Vieweg. 2003. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendrific cells. Cancer Res. 63:2127.
57. Gordan, J. D., and R. H. Vonderheide. 2002. Universal tumor antigens as targets for immunotherapy. Cytotherapy 4:317.
58. Greten, T. F., and E. M. Jaffee. 1999. Cancer vaccines. J. Clin. Oncol. 17:1047.
59. Davis, I. D. 2000. An overview of cancer immunotherapy. Immunol. Cell Biol. 78:179.
60. Tamura, Y., P. Peng, K. Liu, M. Daou, and P. K. Srivastava. 1997. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278:117.
61. Melcher, A., S. Todryk, N. Hardwick, M. Ford, M. Jacobson, and R. G. Vile. 1998. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med. 4:581.